Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

BACKGROUND: Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast cancer (HER2(+) mBC) but has some safety issues due to taxane-induced toxicities. This has led to ongoing efforts to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Toshinari, Masuda, Norikazu, Saji, Shigehira, Araki, Kazuhiro, Ito, Yoshinori, Takano, Toshimi, Takahashi, Masato, Tsurutani, Junji, Koizumi, Kei, Kitada, Masahiro, Kojima, Yasuyuki, Sagara, Yasuaki, Tada, Hiroshi, Iwasa, Tsutomu, Kadoya, Takayuki, Iwatani, Tsuguo, Hasegawa, Hiroki, Morita, Satoshi, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206765/
https://www.ncbi.nlm.nih.gov/pubmed/32381018
http://dx.doi.org/10.1186/s13063-020-04341-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206765/
https://www.ncbi.nlm.nih.gov/pubmed/32381018
http://dx.doi.org/10.1186/s13063-020-04341-y

Ejemplares similares